.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
Mallinckrodt
Chinese Patent Office
Dow
Accenture
AstraZeneca
Johnson and Johnson
QuintilesIMS
Argus Health

Generated: December 13, 2017

DrugPatentWatch Database Preview

LUXIQ Drug Profile

« Back to Dashboard

When do Luxiq patents expire, and when can generic versions of Luxiq launch?

Luxiq is a drug marketed by Mylan Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in twenty countries.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.
Drug patent expirations by year for LUXIQ

Pharmacology for LUXIQ

Medical Subject Heading (MeSH) Categories for LUXIQ

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms IncLUXIQbetamethasone valerateAEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LUXIQ

Drugname Dosage Strength RLD Submissiondate
betamethasone valerateFoam0.12%Luxiq8/10/2007

Non-Orange Book Patents for Tradename: LUXIQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,126,920 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LUXIQ

Country Document Number Estimated Expiration
Portugal813413► Subscribe
Slovakia119097► Subscribe
Denmark0813413► Subscribe
Brazil9607687► Subscribe
China1082817► Subscribe
Australia709320► Subscribe
JapanH11501045► Subscribe
Slovakia283049► Subscribe
Germany69630593► Subscribe
New Zealand302727► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
AstraZeneca
Merck
UBS
Dow
Boehringer Ingelheim
Healthtrust
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot